• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Request Free Sample

    ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Anti obesity Drugs Market

    ID: MRFR/Pharma/57644-CR
    184 Pages
    Rahul Gotadki
    July 2025

    Anti-obesity Drugs Market Research Report Information by Treatment Type (Appetite Suppressants (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others), by Drug Type (Prescription Drugs and Over the Counter Drugs), by Mechanism of Action (Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs), by Route of Administration (Oral and Subcutaneous), by Distribution Ch...

    Share:

    Download PDF

    ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Anti-obesity Drugs Market Research Report – Forecast Till 2035 Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Anti obesity Drugs Market Summary

    The Global Anti-obesity Drugs Market is projected to grow significantly from 235.94 USD Billion in 2024 to 541.32 USD Billion by 2035.

    Key Market Trends & Highlights

    Anti-obesity Drugs Key Trends and Highlights

    • The market is expected to exhibit a compound annual growth rate (CAGR) of 7.84 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 541.32 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 235.94 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of anti-obesity drugs due to increasing obesity rates is a major market driver.

    Market Size & Forecast

    2024 Market Size 235.94 (USD Billion)
    2035 Market Size 541.32 (USD Billion)
    CAGR (2025 - 2035) 7.84%
    Largest Regional Market Share in 2024 -)

    Major Players

    Apple Inc (US), Microsoft Corp (US), Amazon.com Inc (US), Alphabet Inc (US), Berkshire Hathaway Inc (US), Tesla Inc (US), Meta Platforms Inc (US), Johnson & Johnson (US), Visa Inc (US), Procter & Gamble Co (US)

    Anti obesity Drugs Market Trends

    The increasing prevalence of obesity worldwide necessitates a multifaceted approach to treatment, with anti-obesity drugs emerging as a pivotal component of comprehensive weight management strategies.

    U.S. Food and Drug Administration (FDA)

    Anti obesity Drugs Market Drivers

    Rising Obesity Rates

    The increasing prevalence of obesity globally serves as a primary driver for the Global Anti-obesity Drugs Market Industry. According to recent statistics, the World Health Organization indicates that obesity rates have nearly tripled since 1975. This alarming trend is prompting healthcare systems to seek effective pharmacological interventions. The market is projected to reach 235.94 USD Billion in 2024, reflecting the urgent need for solutions to combat obesity-related health issues such as diabetes and cardiovascular diseases. As awareness grows, the demand for anti-obesity drugs is expected to surge, further propelling market growth.

    Increased Health Awareness

    Growing awareness regarding the health risks associated with obesity is driving the Global Anti-obesity Drugs Market Industry. Public health campaigns and educational initiatives are effectively informing populations about the dangers of obesity, including its links to chronic diseases. This heightened awareness is leading to an increased demand for anti-obesity medications as individuals seek effective solutions for weight management. As a result, the market is expected to expand significantly, with projections indicating a rise to 541.32 USD Billion by 2035. This trend suggests that informed consumers are more likely to pursue pharmacological options to complement lifestyle changes.

    Rising Healthcare Expenditure

    The escalation of healthcare spending globally is a significant driver for the Global Anti-obesity Drugs Market Industry. As nations allocate more resources to healthcare, there is a corresponding increase in the budget for obesity treatment options. This trend is particularly evident in developed countries, where healthcare systems are prioritizing the management of obesity-related conditions. The anticipated growth of the market to 541.32 USD Billion by 2035 reflects this shift in expenditure. As healthcare providers recognize the long-term cost savings associated with effective obesity management, investment in anti-obesity drugs is likely to rise, further fueling market expansion.

    Advancements in Drug Development

    Innovations in pharmaceutical research and development are significantly influencing the Global Anti-obesity Drugs Market Industry. Recent advancements in biotechnology and pharmacogenomics have led to the creation of more effective and targeted anti-obesity medications. For instance, the introduction of GLP-1 receptor agonists has shown promising results in weight management. These developments not only enhance treatment efficacy but also improve patient compliance. As the market evolves, the anticipated growth from 235.94 USD Billion in 2024 to 541.32 USD Billion by 2035, with a CAGR of 7.84% from 2025 to 2035, underscores the potential of these innovations.

    Government Initiatives and Support

    Government policies aimed at combating obesity are playing a crucial role in shaping the Global Anti-obesity Drugs Market Industry. Various countries are implementing strategies to address the obesity epidemic, including funding for research and development of anti-obesity drugs. For example, initiatives that promote access to weight management therapies and subsidies for obesity treatments are becoming more common. Such support not only encourages pharmaceutical companies to invest in anti-obesity drug development but also facilitates patient access to these medications. This proactive approach is likely to contribute to the market's growth trajectory, aligning with the projected increase in market value.

    Market Segment Insights

    Anti-Obesity Drugs by Treatment Type Insights

    Based on Treatment Type, this segment includes Appetite Suppressants (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin 2C Receptor Agonists, Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)), Lipase Inhibitors, GLP-1 Receptor Agonists, Combination Drugs, Others.

    The GLP-1 Receptor Agonists segment dominated the global market in 2024, while the Combination Drugs segment is projected to be the fastest–growing segment during the forecast period.

    GLP-1 Receptor Agonists have become a cornerstone in the development of anti-obesity drugs, offering a highly effective solution for weight management. Initially designed to treat type 2 diabetes, these medications, including semaglutide (Wegovy) and liraglutide (Saxenda), work by mimicking the natural hormone GLP-1 to regulate appetite, food intake, and glucose metabolism.

    Through mechanisms such as appetite suppression, increased satiety, and improved insulin sensitivity, GLP-1 receptor agonists have demonstrated significant efficacy in promoting sustained weight loss, with clinical trials showing reductions of up to 15-20% of body weight in patients.

    Their dual benefit of managing obesity and enhancing metabolic health makes them particularly attractive for individuals with obesity-related conditions like type 2 diabetes and cardiovascular risk factors.

    Anti-Obesity Drugs by Drug Type Insights

    Based on Drug Type, this segment includes Prescription Drugs and Over the Counter Drugs. The Prescription Drugs segment dominated the global market in 2024, while the Over the Counter Drugs segment is projected to be the fastest–growing segment during the forecast period.

    Prescription anti-obesity drugs are a key component in the treatment of obesity, particularly for individuals who have been unable to achieve significant weight loss through lifestyle changes alone.

    These medications are typically prescribed for patients with a body mass index (BMI) of 30 or higher, or 27 or higher with obesity-related health issues, such as diabetes or hypertension.

    Among the most prescribed options are appetite suppressants like Phentermine, fat absorption inhibitors such as Orlistat, and GLP-1 receptor agonists like Semaglutide and Liraglutide. These drugs work by reducing hunger, enhancing feelings of fullness, or blocking fat absorption, helping patients achieve and maintain weight loss.

    Anti-Obesity Drugs by Mechanism of Action Insights

    Based on Mechanism of Action, this segment includes Centrally Acting Anti-Obesity Drugs and Peripherally Acting Anti-Obesity Drugs.

    The Centrally Acting Anti-Obesity Drugs segment dominated the global market in 2024, while the Peripherally Acting Anti-Obesity Drugs segment is projected to be the fastest–growing segment during the forecast period.

    Centrally acting anti-obesity medications are an important option in the treatment of obesity, targeting the brain's appetite-control centers to help manage hunger and food intake.

    By affecting key neurotransmitters like norepinephrine, serotonin, and dopamine, these drugs work to reduce appetite, minimize cravings, and support weight loss.

    Prominent examples include Phentermine, a short-term appetite suppressant, and Phentermine-Topiramate (Qsymia), a combination treatment that boosts appetite control and energy expenditure.

    Anti-Obesity Drugs by Route of Administration Insights

    Based on Route of Administration, this segment includes Oral and Subcutaneous. The Subcutaneous segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period.

    The subcutaneous route of administration is emerging as a key player in the anti-obesity drugs market, driven by its ability to offer sustained and controlled drug release.

    Subcutaneous injections, such as those used with GLP-1 receptor agonists like Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda), provide more consistent blood levels and enhanced efficacy in weight loss and metabolic control.

    These injectable drugs reduce appetite, increase satiety, and regulate glucose, offering a significant advantage over oral medications, particularly for patients with more severe obesity or comorbidities like type 2 diabetes.

    The subcutaneous route ensures better bioavailability and allows for less frequent dosing, improving patient adherence. While the method may present challenges in patient comfort and acceptance, the growing adoption of subcutaneous therapies reflects their strong position in the market, catering to patients seeking a more targeted and effective solution for weight management.

    Anti-Obesity Drugs by Distribution Channel Insights

    Based on Distribution Channel, this segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

    The Hospital Pharmacies segment dominated the global market in 2024, while the Online Pharmacies segment is projected to be the fastest–growing segment during the forecast period.

    Hospital pharmacies play a crucial role as a distribution channel in the anti-obesity drug market, particularly for patients who require more specialized care or treatment regimens.

    These pharmacies are integral in the distribution of prescription-based anti-obesity medications, including GLP-1 receptor agonists, centrally acting drugs, and combination therapies, often prescribed for individuals with severe obesity or obesity-related comorbidities, such as type 2 diabetes, hypertension, or cardiovascular disease.

    Hospital pharmacies offer a highly controlled environment where patients can receive personalized counselling, precise dosing instructions, and tailored medication plans.

    Get more detailed insights about Anti-obesity Drugs Market Research Report – Forecast Till 2035

    Request Free Sample

    Regional Insights

    Based on the Region, the global Anti-obesity Drugs are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa.

    The North America dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the North America market are the rising prevalence of obesity and increasing government initiatives and support.

    Government support and favorable policies also play a pivotal role in the market's expansion. Initiatives like Medicare’s proposal to cover anti-obesity drugs have opened doors for wider access to treatments, making these drugs more affordable and accessible to millions of Americans.

    Additionally, the Food and Drug Administration's (FDA) approval of new anti-obesity medications, including GLP-1 receptor agonists like semaglutide (Wegovy), has driven significant growth, with these treatments demonstrating considerable effectiveness in weight reduction.

    FIGURE 3: ANTI-OBESITY DRUGS MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)

    ANTI-OBESITY DRUGS MARKET VALUE BY REGION 2024 AND 2035

    Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

    Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

    Key Players and Competitive Insights

    Many global, regional, and local vendors characterize the Anti-obesity Drugs Market. The market is highly competitive, with all the players competing to gain market share.

    Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.

    The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

    The major competitors in the market are Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, CHEPLAPHARM Arzneimittel GmbH, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC are among others.

    The Anti-obesity Drugs Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

    Key Companies in the Anti obesity Drugs Market market include

    Industry Developments

    Future Outlook

    Anti obesity Drugs Market Future Outlook

    The Global Anti-obesity Drugs Market is projected to grow at a 7.84% CAGR from 2024 to 2035, driven by rising obesity rates, increased healthcare expenditure, and advancements in drug development.

    New opportunities lie in:

    • Develop personalized anti-obesity therapies targeting genetic predispositions.
    • Leverage digital health technologies for remote patient monitoring and adherence.
    • Expand market presence in emerging economies with tailored marketing strategies.

    By 2035, the market is expected to demonstrate robust growth, reflecting evolving consumer needs and innovative therapeutic solutions.

    Market Segmentation

    Anti-obesity Drugs Regional Outlook

    • US
    • Canada

    Anti-obesity Drugs by Drug Type Outlook

    • Prescription Drugs
    • Over the Counter Drugs

    Anti-obesity Drugs by Treatment Type Outlook

    • Serotonin-Norepinephrine Reuptake Inhibitors
    • Selective Serotonin 2C Receptor Agonists
    • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)

    Anti-obesity Drugs by Mechanism of Action Outlook

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Anti-obesity Drugs by Distribution Channel Outlook

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Anti-obesity Drugs by Route of Administration Outlook

    • Oral
    • Subcutaneous

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024 USD 27.16 Billion
    Market Size 2025 USD 32.89 Billion
    Market Size 2035 USD 326.90 Billion
    Compound Annual Growth Rate (CAGR) 25.82% (2025-2035)
    Base Year 2024
    Forecast Period 2025-2035
    Historical Data 2019-2023
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered By Treatment Type, By Drug Type, By Mechanism of Action, By Route of Administration, By Distribution Channel
    Geographies Covered North America, Europe, Asia Pacific, South America, Middle East & Africa
    Countries Covered The US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa
    Key Companies Profiled Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, CHEPLAPHARM Arzneimittel GmbH, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC
    Key Market Opportunities ·         Focus on non-surgical obesity treatments
    Key Market Dynamics ·         Rising prevalence of obesity ·         Increasing government initiative and support

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    How much is the Anti-obesity Drugs Market?

    USD 27.16 Billion is the Anti-obesity Drugs Market in 2024

    Which Drug Type holds the largest market share?

    The Prescription Drugs segment by Drug Type holds the largest market share and grows at a CAGR of 25.67 % during the forecast period.

    Which region holds the largest market share in the Anti-obesity Drugs Market?

    North America holds the largest market share in the Anti-obesity Drugs Market.

    Who are the prominent players in the Anti-obesity Drugs Market?

    Eli Lilly and Company, AstraZeneca, GSK Plc, Gelesis, CHEPLAPHARM Arzneimittel GmbH, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., KVK Tech, Inc., Currax Pharmaceuticals LLC, VIVUS LLC are prominent players in the Anti-obesity Drugs Market.

    Which Treatment Type segment led the Anti-obesity Drugs Market?

    The GLP-1 Receptor Agonists segment dominated the market in 2024.

    1. EXECUTIVE SUMMARY
    2. MARKET INTRODUCTION
      1. DEFINITION
      2. SCOPE OF THE STUDY
      3. RESEARCH OBJECTIVE
      4. MARKET STRUCTURE
    3. RESEARCH METHODOLOGY
      1. OVERVIEW
      2. DATA FLOW
        1. DATA MINING PROCESS
      3. PURCHASED DATABASE:
      4. SECONDARY SOURCES:
        1. SECONDARY RESEARCH DATA FLOW:
      5. PRIMARY RESEARCH:
        1. PRIMARY
        2. PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
        3. PRIMARY RESEARCH: REGIONAL COVERAGE
      6. APPROACHES FOR MARKET SIZE
        1. REVENUE ANALYSIS APPROACH
      7. DATA FORECASTING
        1. DATA FORECASTING TYPE
      8. DATA MODELING
        1. MICROECONOMIC FACTOR ANALYSIS:
        2. DATA MODELING:
      9. TEAMS AND ANALYST CONTRIBUTION
    4. MARKET DYNAMICS
      1. INTRODUCTION
      2. DRIVERS
        1. RISING PREVALENCE OF OBESITY
        2. INCREASING GOVERNMENT INITIATIVES AND SUPPORT
      3. RESTRAINTS
        1. SIDE
      4. OPPORTUNITY
        1. FOCUS ON NON-SURGICAL
    5. MARKET FACTOR ANALYSIS
      1. PORTER'S FIVE FORCES MODEL
        1. THREAT OF NEW ENTRANTS
        2. BARGAINING POWER OF SUPPLIERS
        3. THREAT OF SUBSTITUTES
        4. BARGAINING POWER OF BUYERS
        5. INTENSITY
      2. IMPACT OF COVID-19 ON GLOBAL ANTI-OBESITY DRUGS MARKET
      3. MARKET TRENDS
      4. REGULATORY LANDSCAPE
        1. NORTH AMERICA
        2. EUROPE
        3. ASIA-PACIFIC
        4. LATIN AMERICA
        5. MIDDLE EAST AND
      5. UNMET NEEDS
      6. EPIDEMIOLOGY ASSESSMENT
      7. BRAND AND
      8. PRICING ANALYSIS
    6. GLOBAL ANTI-OBESITY DRUGS MARKET,
      1. OVERVIEW
      2. APPETITE SUPPRESSANTS
        1. SEROTONIN-NOREPINEPHRINE
        2. SELECTIVE SEROTONIN 2C RECEPTOR AGONISTS
        3. NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS (NDRIS)
      3. LIPASE INHIBITORS
      4. GLP-1 RECEPTOR AGONISTS
      5. COMBINATION DRUGS
      6. OTHERS
    7. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DRUG TYPE
      1. OVERVIEW
      2. PRESCRIPTION
      3. OVER THE COUNTER DRUGS
    8. GLOBAL ANTI-OBESITY DRUGS MARKET, BY
      1. OVERVIEW
      2. CENTRALLY ACTING ANTI-OBESITY DRUGS
      3. PERIPHERALLY ACTING ANTI-OBESITY DRUGS
    9. GLOBAL ANTI-OBESITY DRUGS MARKET,
      1. OVERVIEW
      2. ORAL
      3. SUBCUTANEOUS
    10. GLOBAL ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL
      1. OVERVIEW
      2. HOSPITAL PHARMACIES
      3. RETAIL PHARMACIES
      4. ONLINE PHARMACIES
    11. GLOBAL ANTI-OBESITY DRUGS MARKET, BY REGION
      1. OVERVIEW
      2. NORTH
        1. US
        2. CANADA
      3. EUROPE
        1. GERMANY
        2. FRANCE
        3. UK
        4. SPAIN
        5. ITALY
        6. RUSSIA
        7. REST OF EUROPE
      4. ASIA PACIFIC
        1. CHINA
        2. INDIA
        3. JAPAN
        4. SOUTH KOREA
        5. MALAYSIA
        6. THAILAND
        7. INDONESIA
        8. REST OF ASIA PACIFIC
      5. SOUTH AMERICA
        1. BRAZIL
        2. MEXICO
        3. ARGENTINA
        4. REST OF SOUTH AMERICA
      6. MIDDLE EAST AND AFRICA
        1. GCC COUNTRIES
        2. SOUTH AFRICA
        3. REST OF MEA
    12. COMPETITIVE LANDSCAPE
      1. INTRODUCTION
      2. MARKET SHARE ANALYSIS, 2024
      3. COMPETITOR DASHBOARD
      4. PUBLIC PLAYERS
      5. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
      6. KEY
        1. PRODUCT APPROVAL
        2. MARKETING
        3. PRODUCT EXPANSION
        4. FACILITY LAUNCH
        5. AQUISITION
        6. AGREEMENT
    13. COMPANY PROFILES
      1. ELI LILLY AND COMPANY
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      2. ASTRAZENECA
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      3. GSK PLC
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCT OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      4. GELESIS
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      5. CHEPLAPHARM ARZNEIMITTEL GMBH
        1. COMPANY
        2. FINANCIAL OVERVIEW
        3. PRODUCT OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      6. NOVO NORDISK A/S
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT ANALYSIS
        6. KEY STRATEGIES
      7. RHYTHM PHARMACEUTICALS, INC.
        1. COMPANY OVERVIEW
        2. FINANCIAL
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. SWOT
        6. KEY STRATEGIES
      8. KVK TECH, INC.
        1. COMPANY
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      9. CURRAX PHARMACEUTICALS LLC
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
      10. VIVUS LLC
        1. COMPANY OVERVIEW
        2. FINANCIAL OVERVIEW
        3. PRODUCTS OFFERED
        4. KEY DEVELOPMENTS
        5. KEY STRATEGIES
    14. DATA CITATIONS

    Global Outlook (USD Billion,2019-2035)

     

    Global Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Global Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Global Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Global Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Global Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    North America Outlook (USD Billion,2019-2035)

     

    North America Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    North America Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    North America Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    North America Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    North America Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    US Outlook (USD Billion,2019-2035)

     

    US Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    US Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    US Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    US Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    US Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Canada Outlook (USD Billion,2019-2035)

     

    Canada Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Canada Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Canada Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Canada Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Canada Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Europe Outlook (USD Billion,2019-2035)

     

    Europe Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Europe Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Europe Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Europe Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Europe Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Germany Outlook (USD Billion,2019-2035)

     

    Germany Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Germany Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Germany Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Germany Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Germany Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    France Outlook (USD Billion,2019-2035)

     

    France Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    France Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    France Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    France Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    France Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    UK Outlook (USD Billion,2019-2035)

     

    UK Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    UK Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    UK Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    UK Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    UK Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Spain Outlook (USD Billion,2019-2035)

     

    Spain Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Spain Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Spain Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Spain Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Spain Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Italy Outlook (USD Billion,2019-2035)

    Italy Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Italy Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Italy Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Italy Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Italy Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Russia Outlook (USD Billion,2019-2035)

    Russia Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Russia Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Russia Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Russia Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Russia Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Rest of Europe Outlook (USD Billion,2019-2035)

     

    Rest of Europe Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Rest of Europe Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Rest of Europe Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Rest of Europe Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Rest of Europe Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Asia-Pacific Outlook (USD Billion,2019-2035)

     

    Asia-Pacific Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Asia-Pacific Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Asia-Pacific Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Asia-Pacific Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Asia-Pacific Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    China Outlook (USD Billion,2019-2035)

     

    China Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
    • Serotonin-Norepinephrine Reuptake Inhibitors
    • Selective Serotonin 2C Receptor Agonists

    Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)

    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs
    • Others

    China Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    China Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    China Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    China Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    India Outlook (USD Billion,2019-2035)

     

    India Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    India Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    India Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    India Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    India Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Japan Outlook (USD Billion,2019-2035)

     

    Japan Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Japan Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Japan Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Japan Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Japan Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    South Korea Outlook (USD Billion,2019-2035)

     

    South Korea Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    South Korea Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    South Korea Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    South Korea Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    South Korea Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Malaysia Outlook (USD Billion,2019-2035)

     

    Malaysia Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Malaysia Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Malaysia Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Malaysia Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Malaysia Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Thailand Outlook (USD Billion,2019-2035)

     

    Thailand Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Thailand Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Thailand Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Thailand Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Thailand Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Indonesia Outlook (USD Billion,2019-2035)

    Indonesia Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Indonesia Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Indonesia Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Indonesia Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Indonesia Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Rest of Asia-Pacific Outlook (USD Billion,2019-2035)

     

    Rest of Asia-Pacific Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Rest of Asia-Pacific Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Rest of Asia-Pacific Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Rest of Asia-Pacific Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Rest of Asia-Pacific Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    South America Outlook (USD Billion,2019-2035)

     

    South America Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    South America Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    South America Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    South America Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    South America Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Brazil Outlook (USD Billion,2019-2035)

    Brazil Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    Appetite Suppressants

    • Serotonin-Norepinephrine Reuptake Inhibitors
    • Selective Serotonin 2C Receptor Agonists

    Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)

    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs
    • Others

    Brazil Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Brazil Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Brazil Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Brazil Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Mexico Outlook (USD Billion,2019-2035)

     

    Mexico Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Mexico Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Mexico Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Mexico Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Mexico Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Argentina Outlook (USD Billion,2019-2035)

     

    Argentina Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Argentina Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Argentina Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Argentina Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Argentina Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Rest of South America Outlook (USD Billion,2019-2035)

     

    Rest of South America Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Rest of South America Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Rest of South America Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Rest of South America Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Rest of South America Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Middle East & Africa Outlook (USD Billion,2019-2035)

     

    Middle East & Africa Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Middle East & Africa Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Middle East & Africa Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Middle East & Africa Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Middle East & Africa Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    GCC Countries Outlook (USD Billion,2019-2035)

     

    GCC Countries Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    GCC Countries Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    GCC Countries Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    GCC Countries Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    GCC Countries Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    South Africa Outlook (USD Billion,2019-2035)

     

    South Africa Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    South Africa Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    South Africa Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    South Africa Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    South Africa Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

    Rest of Middle East & Africa Outlook (USD Billion,2019-2035)

     

    Rest of Middle East & Africa Anti-obesity Drugs, By Treatment Type (USD Billion,2019-2035)

    • Appetite Suppressants
      • Serotonin-Norepinephrine Reuptake Inhibitors
      • Selective Serotonin 2C Receptor Agonists
      • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
    • Lipase Inhibitors
    • GLP-1 Receptor Agonists
    • Combination Drugs

    Rest of Middle East & Africa Anti-obesity Drugs, By Drug Type (USD Billion,2019-2035)

    • Prescription Drugs
    • Over the Counter Drugs

    Rest of Middle East & Africa Anti-obesity Drugs, By Mechanism of Action (USD Billion,2019-2035)

    • Centrally Acting Anti-Obesity Drugs
    • Peripherally Acting Anti-Obesity Drugs

    Rest of Middle East & Africa Anti-obesity Drugs, By Route of Administration (USD Billion,2019-2035)

    • Oral
    • Subcutaneous

    Rest of Middle East & Africa Anti-obesity Drugs, By Distribution Channel (USD Billion,2019-2035)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    Report Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027